NEONATAL BARTTER-SYNDROME - USE OF INDOMETHACIN IN THE NEWBORN PERIODAND PREVENTION OF GROWTH FAILURE

Neonatal Bartter syndrome differs from the classical Bartter syndrome in the occurrence of antenatal presentation with polyhydramnios. Nephr ocalcinosis and severe growth retardation are common sequelae. Indomet hacin has been reported to improve linear growth, but its use in the e arly newborn period has been infrequently described. In this paper we report normal growth and development and the absence of nephrocalcinos is in an infant now aged 19 months with neonatal Bartter syndrome trea ted from day 3 of life with indomethacin. With early diagnosis and tre atment with indomethacin plus adequate water, calories, and sodium, no rmal growth can be achieved and nephrocalcinosis may be prevented in c hildren with neonatal Bartter syndrome.